COVID–19 eliminating PPE
Virucidal, Antiviral & Antimicrobial PPE that starts eliminating SARS-CoV-2, other viruses, and bacteria within minutes of contact*
Packing a punch
PPE that fights back
A subsidiary of ViraCorp, ViraCoat has developed a novel Virucidal, Antiviral & Antimicrobial Coating which has been demonstrated to have profound antiviral properties against SARS-CoV-2 (including new strains), Influenza (PR8 strain), and Bacteria (E. coli).
This proprietary Coating can be applied to and incorporated into PPE and other products to inactivate the virus and help to reduce the spread of COVID-19 and other infectious diseases.
Through partnership with world-leading experts at one of the UK’s most prestigious universities, all of our products have undergone thorough testing in both clinical and real-world environments.
Using live strains of virus within a Containment Level 3 laboratory, ViraCoat products have achieved all required certifications in addition to certifications which demonstrate proof of profound antiviral capabilities.
All masks are manufactured within a facility that is compliant with Module D of the Personal Protective Equipment (PPE) Regulation (EU) 2016/425.
Our manufacturing facility is under surveillance of both an EU Notified Body & a UK approved body that allows the product to be marked both CE & UKCA.
- EN 149:2001 + A1 2009 FFP2
- CE 0598
- UKCA 0120
- ISO 18184:2019 (Textiles – determination of antiviral activity in textile products)
- ISO 10993-1:2018 (Biological evaluation of medical devices (safety, cytotoxicity, dermal & skin sensitisation))
A multi-faceted approach to protecting the world’s health
ViraCoat is part of ViraCorp
ViraCorp through its subsidiaries are a group of biomedical research and development companies, on a mission to improve the health outcomes for as many of the world’s population as possible.
Specifically focusing on protecting and preventing the disastrous humanitarian and economic impacts of viral outbreaks, pandemics and endemic infections, ViraCorp is taking an innovative, disruptive approach to developing viral defence products.
ViraCorp has a formidable combination of unique Intellectual Property, world-class researchers and facilities, and a multidisciplinary, seasoned management team that uniquely position it for success.